5 completed, 2 withdrawn, 1 unknown. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Withdrawn 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Renal Disease: new trials by email Literature Review of Renal Disease trials Research Report on Renal Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects Nitazoxanide - Renal Impairment, Renal Disease | Phase 1 | Completed | Genfit | 77 | 2022-04-25 | 2022-10-28 |
| A Pharmacokinetic Study of Sugammadex in Dialysis Patients Sugammadex - Renal Disease | Phase 1 | Withdrawn | Tetsuro Sakai | 2021-09-10 | 2021-09-17 | |
| Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function Venetoclax - Renal Impairment, Renal Disease | Phase 1 | Completed | AbbVie | 12 | 2021-07-08 | 2022-09-16 |
| Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases AntiSARS-CoV-2 Serum, Placebo - Immunosuppression, Cancer | Phase 1 / Phase 2 | Unknown | Butantan Institute | 618 | 2021-05-01 | 2021-04-08 |
| Extragonadal Effects of hCG on Calcium Homeostasis human chorionic gonadotropin - Hypogonadism, Calcium Disorder | Phase 1 | Completed | Martin Blomberg Jensen | 12 | 2018-01-06 | 2023-06-13 |
| Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation IdeS® (Imlifidase) - Renal Disease | Phase 1 / Phase 2 | Completed | Cedars-Sinai Medical Center | 17 | 2015-06-16 | 2022-05-16 |
| A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects 200 mg Ceftaroline fosamil, 600 mg Ceftaroline fosamil - Renal Disease | Phase 1 | Completed | Pfizer | 15 | 2013-02-01 | 2017-09-05 |
| A Multi-Center, Open-Label Study Droxidopa - Renal Disease, End Stage Renal Disease | Phase 1 | Withdrawn | Chelsea Therapeutics | 2012-10-01 | 2013-03-29 |
Kidney Diseases (8) · Kidney Failure, Chronic (3) · Renal Insufficiency (2) · COVID-19 (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Hypogonadism (1) · Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Male Urogenital Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Renal Insufficiency, Chronic (3) · Endocrine System Diseases (2) · Renal Insufficiency (2) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Glucose Metabolism Disorders (1)
Ceftaroline (1) · Chorionic Gonadotropin (1) · Droxidopa (1) · Sugammadex (1) · nitazoxanide (1) · venetoclax (1)
AbbVie (1) · Butantan Institute (1) · Cedars-Sinai Medical Center (1) · Chelsea Therapeutics (1) · Genfit (1) · Martin Blomberg Jensen (1) · Pfizer (1) · Tetsuro Sakai (1)
United States (5) · Brazil (1) · Denmark (1) · United Kingdom (1)
Arpeat Kaviya, MBChB, MRCP (1) · Carol Addy, MD (1) · David Melnick, MD (1) · Mirjana Kujacic, MD (1) · Ricardo Palacios, MD, PhD (1) · Stanley C Jordan, MD (1) · Tetsuro Sakai, MD, PhD, MHA (1) · William D Schweiterman, MD (1)
PMID 28767349, PMID 30380060, PMID 33809538, PMID 38852333
2016 (1)